Rathnasinghe, Raveen
Karlicek, Robert F. Jr.
Schotsaert, Michael
Koffas, Mattheos
Arduini, Brigitte L.
Jangra, Sonia
Wang, Bowen
Davis, Jason L.
Alnaggar, Mohammed
Costa, Anthony
Vincent, Richard
García-Sastre, Adolfo
Vashishth, Deepak
Balchandani, Priti
Funding for this research was provided by:
NIAID supported Center of Excellence for Influenza Research and Surveillance (HHSN272201400008C)
Funds from Rensselaer Polytechnic Institute
NIH CTSA (5UL1TR001433)
Center for Research for Influenza Pathogenesis
JPB Foundation
Open Philanthropy Project (2020-215611 (5384))
Article History
Received: 20 December 2020
Accepted: 16 September 2021
First Online: 7 October 2021
Competing interests
: A patent application has been submitted by Rensselaer Polytechnic Institute on the use of UVC sterilization devices for viral inactivation. None of the authors have a financial interest in the commercialization of the UVC system described in this paper. The García-Sastre Laboratory has received research support from Pfizer, Senhwa Biosciences, 7Hills Pharma, Pharmamar, Blade Therapeutics, Avimex, Accurius, Dynavax, Kenall Manufacturing, ImmunityBio and Nanocomposix; and A.G.-S. has consulting agreements for the following companies involving cash and/or stock: Vivaldi Biosciences, Pagoda, Contrafect, Vaxalto, Accurius, 7Hills Pharma, Avimex, Esperovax and Farmak. There is no other financial or non-financial conflict of interest by the rest of the authors apart from currently declared.